144 related articles for article (PubMed ID: 36869329)
1. Multiomics analysis revealed the mechanisms related to the enhancement of proliferation, metastasis and EGFR-TKI resistance in EGFR-mutant LUAD with ARID1A deficiency.
Sun D; Feng F; Teng F; Xie T; Wang J; Xing P; Qian H; Li J
Cell Commun Signal; 2023 Mar; 21(1):48. PubMed ID: 36869329
[TBL] [Abstract][Full Text] [Related]
2. ARID1A deficiency reverses the response to anti-PD(L)1 therapy in EGFR-mutant lung adenocarcinoma by enhancing autophagy-inhibited type I interferon production.
Sun D; Qian H; Wang J; Xie T; Teng F; Li J; Xing P
Cell Commun Signal; 2022 Oct; 20(1):156. PubMed ID: 36229854
[TBL] [Abstract][Full Text] [Related]
3. Loss of ARID1A expression promotes lung adenocarcinoma metastasis and predicts a poor prognosis.
Sun D; Zhu Y; Zhao H; Bian T; Li T; Liu K; Feng L; Li H; Hou H
Cell Oncol (Dordr); 2021 Oct; 44(5):1019-1034. PubMed ID: 34109546
[TBL] [Abstract][Full Text] [Related]
4. APE1 stimulates EGFR-TKI resistance by activating Akt signaling through a redox-dependent mechanism in lung adenocarcinoma.
Lu GS; Li M; Xu CX; Wang D
Cell Death Dis; 2018 Oct; 9(11):1111. PubMed ID: 30382076
[TBL] [Abstract][Full Text] [Related]
5. ADAM12 promotes the resistance of lung adenocarcinoma cells to EGFR-TKI and regulates the immune microenvironment by activating PI3K/Akt/mTOR and RAS signaling pathways.
Li K; Quan L; Huang F; Li Y; Shen Z
Int Immunopharmacol; 2023 Sep; 122():110580. PubMed ID: 37418984
[TBL] [Abstract][Full Text] [Related]
6. Targeting 14-3-3ζ Overcomes Resistance to Epidermal Growth Factor Receptor-Tyrosine Kinase Inhibitors in Lung Adenocarcinoma via BMP2/Smad/ID1 Signaling.
Cui J; Song Y; Han X; Hu J; Chen Y; Chen X; Xu X; Xing Y; Lu H; Cai L
Front Oncol; 2020; 10():542007. PubMed ID: 33123465
[No Abstract] [Full Text] [Related]
7. CXCR1 correlates to poor outcomes of EGFR-TKI against advanced non-small cell lung cancer by activating chemokine and JAK/STAT pathway.
Yang F; Zhang S; Meng Q; Zhou F; Pan B; Liu F; Yu Y
Pulm Pharmacol Ther; 2021 Apr; 67():102001. PubMed ID: 33582208
[TBL] [Abstract][Full Text] [Related]
8. C1orf74 positively regulates the EGFR/AKT/mTORC1 signaling in lung adenocarcinoma cells.
Guo J; Li A; Guo R; He Q; Wu Y; Gou Y; Jin J; Huang G
PeerJ; 2022; 10():e13908. PubMed ID: 36032960
[TBL] [Abstract][Full Text] [Related]
9. ARID1A serves as a receivable biomarker for the resistance to EGFR-TKIs in non-small cell lung cancer.
Sun D; Teng F; Xing P; Li J
Mol Med; 2021 Oct; 27(1):138. PubMed ID: 34715776
[TBL] [Abstract][Full Text] [Related]
10. Plakophilin-2 accelerates cell proliferation and migration through activating EGFR signaling in lung adenocarcinoma.
Hao XL; Tian Z; Han F; Chen JP; Gao LY; Liu JY
Pathol Res Pract; 2019 Jul; 215(7):152438. PubMed ID: 31126818
[TBL] [Abstract][Full Text] [Related]
11. TIMELESS promotes the proliferation and migration of lung adenocarcinoma cells by activating EGFR through AMPK and SPHK1 regulation.
Yin H; Wang Z; Wang D; Nuer M; Han M; Ren P; Ma S; Lin C; Chen J; Xian H; Ai D; Li X; Ma S; Lin Z; Pan Y
Eur J Pharmacol; 2023 Sep; 955():175883. PubMed ID: 37433364
[TBL] [Abstract][Full Text] [Related]
12. NOTCH3 Overexpression and Posttranscriptional Regulation by miR-150 Were Associated With EGFR-TKI Resistance in Lung Adenocarcinoma.
Zhang Y; Chen B; Wang Y; Zhao Q; Wu W; Zhang P; Miao L; Sun S
Oncol Res; 2019 Jul; 27(7):751-761. PubMed ID: 30732676
[TBL] [Abstract][Full Text] [Related]
13. DUSP5 regulated by YTHDF1-mediated m6A modification promotes epithelial-mesenchymal transition and EGFR-TKI resistance via the TGF-β/Smad signaling pathway in lung adenocarcinoma.
Fan W; Xing Y; Yan S; Liu W; Ning J; Tian F; Wang X; Zhan Y; Luo L; Cao M; Huang J; Cai L
Cancer Cell Int; 2024 Jun; 24(1):208. PubMed ID: 38872157
[TBL] [Abstract][Full Text] [Related]
14. HCP5 is a SMAD3-responsive long non-coding RNA that promotes lung adenocarcinoma metastasis via miR-203/SNAI axis.
Jiang L; Wang R; Fang L; Ge X; Chen L; Zhou M; Zhou Y; Xiong W; Hu Y; Tang X; Li G; Li Z
Theranostics; 2019; 9(9):2460-2474. PubMed ID: 31131047
[No Abstract] [Full Text] [Related]
15. STAMBP promotes lung adenocarcinoma metastasis by regulating the EGFR/MAPK signaling pathway.
Xu H; Yang X; Xuan X; Wu D; Zhang J; Xu X; Zhao Y; Ma C; Li D
Neoplasia; 2021 Jun; 23(6):607-623. PubMed ID: 34102455
[TBL] [Abstract][Full Text] [Related]
16. Gene alternation of cerebrospinal fluid in patients with leptomeningeal metastases of lung adenocarcinoma using next-generation sequencing.
Yang H; Wen L; Pan Y; Shan C; Hong W; Wang H; Zhou C; Cai L; Zhou C
BMC Cancer; 2022 May; 22(1):580. PubMed ID: 35614407
[TBL] [Abstract][Full Text] [Related]
17. The impact of PRDX4 and the EGFR mutation status on cellular proliferation in lung adenocarcinoma.
Mizutani K; Guo X; Shioya A; Zhang J; Zheng J; Kurose N; Ishibashi H; Motono N; Uramoto H; Yamada S
Int J Med Sci; 2019; 16(9):1199-1206. PubMed ID: 31588184
[No Abstract] [Full Text] [Related]
18. High expression of keratin 6C is associated with poor prognosis and accelerates cancer proliferation and migration by modulating epithelial-mesenchymal transition in lung adenocarcinoma.
Hu HB; Yang XP; Zhou PX; Yang XA; Yin B
Genes Genomics; 2020 Feb; 42(2):179-188. PubMed ID: 31768767
[TBL] [Abstract][Full Text] [Related]
19. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
20. Targeting YAP-p62 signaling axis suppresses the EGFR-TKI-resistant lung adenocarcinoma.
Park HS; Lee DH; Kang DH; Yeo MK; Bae G; Lee D; Yoo G; Kim JO; Moon E; Huh YH; Lee SH; Jo EK; Cho SY; Lee JE; Chung C
Cancer Med; 2021 Feb; 10(4):1405-1417. PubMed ID: 33486901
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
